Dr. Campbell is responsible for preclinical and early stage development R&D at Axial. He brings 25 years of drug discovery and development experience across multiple therapeutic areas and treatment modalities. He has built and led R&D teams involved in a variety of environments from early stage research through to advanced clinical development in small start-ups to mid-sized companies. Prior to joining Axial, Dr. Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies including Corden Pharma, Surface Logix and Insmed Inc. At Corden Pharma, Dr. Campbell served as Head of Product Management and Business Development for Carbohydrates and Lipids and as Head of Operations for Corden Pharma’s Woburn, MA manufacturing site. Prior to Corden Pharma Dr. Campbell served as Vice President of R&D at Ancora Pharmaceuticals, a synthetic vaccine company, successfully triaging Ancora through the acquisition by and integration into Corden Pharma. While at Surface Logix and Insmed, Dr. Campbell played an integral role in the discovery and development of five clinical stage drug candidates, including small molecules and biotherapeutics. He holds a BSc with Honours in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University, and did post-doctoral research in natural product synthesis at Duke University. He has consulted for several start-up companies in multiple technology and therapeutic areas in the Greater Boston area and is co-inventor on 18 issued patents.